Table 2 Relationship between the expression of TIM-3 and clinicopathological parameters
From: Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
| Â | TIM-3 | P value | |
|---|---|---|---|
Positive | Negative | ||
Total | 92 (56.4) | 71 (43.6) | Â |
Age, n (%) | Â | Â | 0.987 |
 < 70y | 83 (90.2) | 64 (90.1) |  |
 ≥ 70y | 9 (9.8) | 7 (9.9) |  |
Gender, n (%) | Â | Â | 0.259 |
 Male | 57 (53.3) | 50 (46.7) |  |
 Female | 35 (62.5) | 21 (37.5) |  |
ISUP, n (%) | Â | Â | 0.055 |
 < 4 | 67 (79.8) | 40 (65.6) |  |
 ≥ 4 | 17 (20.2) | 21 (34.4) |  |
Histological Type, n(%) | Â | Â | 0.377 |
 ccRCC | 74 (58.3) | 53 (41.7) |  |
 Non-ccRCC | 18 (50.0) | 18 (50.0) |  |
Pathology, n (%) | |||
 Sarcoma | 5 (62.5) | 3 (37.5) | 0.898 |
 Necrosis | 20 (66.7) | 10 (33.3) | 0.958 |
Nephrectomy | Â | Â | 0.026 |
 Yes | 84 (61.3) | 53 (38.7) |  |
 No | 7 (35.0) | 13 (65.0) |  |
ECOG, n (%) | Â | Â | 0.239 |
 0–1 | 68 (60.7) | 44 (39.3) |  |
 ≥ 2 | 20 (50.0) | 20 (50.0) |  |
IMDC, n (%) | Â | Â | 0.030 |
 Low | 23 (69.7) | 10 (30.3) |  |
 Intermediate | 49 (61.3) | 31 (38.7) |  |
 High | 11 (37.9) | 18 (62.1) |  |
T stage, n (%) | Â | Â | 0.391 |
 < 2b | 38 (64.4) | 20 (55.6) |  |
 ≥ 2b | 21 (35.6) | 16 (44.4) |  |
Treatment, n (%) | |||
 Cytokine | 12 (54.5) | 10 (45.5) | 0.762 |
 Targeted therapy | 32 (50.0) | 32 (50.0) | 0.088 |
 Radiotherapy | 7 (50.0) | 7 (50.0) | 0.504 |
 Chemotherapy | 5 (62.5) | 3 (37.5) | 0.817 |